CR20230533A - Un fab anti-tslp con estabilidad mejorada - Google Patents

Un fab anti-tslp con estabilidad mejorada

Info

Publication number
CR20230533A
CR20230533A CR20230533A CR20230533A CR20230533A CR 20230533 A CR20230533 A CR 20230533A CR 20230533 A CR20230533 A CR 20230533A CR 20230533 A CR20230533 A CR 20230533A CR 20230533 A CR20230533 A CR 20230533A
Authority
CR
Costa Rica
Prior art keywords
fab
improved stability
tslp
tslp fab
nucleic acids
Prior art date
Application number
CR20230533A
Other languages
English (en)
Spanish (es)
Inventor
Catherine Eugenie Huntington
Emma Suzanne Cohen
Roland Wilhelm Kolbeck
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of CR20230533A publication Critical patent/CR20230533A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CR20230533A 2021-04-19 2022-04-19 Un fab anti-tslp con estabilidad mejorada CR20230533A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21169183 2021-04-19
PCT/EP2022/060236 WO2022223514A1 (en) 2021-04-19 2022-04-19 An anti-tslp fab with improved stability

Publications (1)

Publication Number Publication Date
CR20230533A true CR20230533A (es) 2024-04-05

Family

ID=75588042

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230533A CR20230533A (es) 2021-04-19 2022-04-19 Un fab anti-tslp con estabilidad mejorada

Country Status (19)

Country Link
US (1) US20240199730A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326767A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024516962A (cg-RX-API-DMAC7.html)
KR (1) KR20230172508A (cg-RX-API-DMAC7.html)
CN (1) CN117222665A (cg-RX-API-DMAC7.html)
AR (1) AR125379A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022263281A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021587A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216894A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003082A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023015286A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230533A (cg-RX-API-DMAC7.html)
EC (1) ECSP23086870A (cg-RX-API-DMAC7.html)
IL (1) IL307651A (cg-RX-API-DMAC7.html)
MX (1) MX2023012266A (cg-RX-API-DMAC7.html)
PH (1) PH12023552762A1 (cg-RX-API-DMAC7.html)
SA (1) SA523451188B1 (cg-RX-API-DMAC7.html)
TW (1) TW202306982A (cg-RX-API-DMAC7.html)
WO (1) WO2022223514A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA129038C2 (uk) * 2019-10-28 2024-12-25 Медіммуне Лімітед Сухий порошкоподібний склад антитіла, що зв'язує тимічний стромальний лімфопоетин (tslp)
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
AR135161A1 (es) 2024-01-29 2026-07-08 Astrazeneca Ab Composiciones de fragmentos de unión a la linfopoyetina estromal tímica (tslp) y métodos de uso de las mismas
USD1126392S1 (en) 2024-05-16 2026-05-12 Astrazeneca Ab Inhaler
US20260034317A1 (en) 2024-05-20 2026-02-05 Medimmune Limited Inhaler and capsule for delivering thymic stromal lymphopoietin (tslp)-binding antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1306272C (zh) 2000-11-17 2007-03-21 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
EP3609917A1 (en) * 2017-04-12 2020-02-19 Amgen Inc. Treatment of asthma with anti-tslp antibody
JP7331298B2 (ja) * 2019-09-04 2023-08-23 ビオシオン インコーポレイテッド 抗体結合tslp及びその使用
UA129038C2 (uk) * 2019-10-28 2024-12-25 Медіммуне Лімітед Сухий порошкоподібний склад антитіла, що зв'язує тимічний стромальний лімфопоетин (tslp)

Also Published As

Publication number Publication date
MX2023012266A (es) 2023-10-24
EP4326767A1 (en) 2024-02-28
IL307651A (en) 2023-12-01
KR20230172508A (ko) 2023-12-22
CL2023003082A1 (es) 2024-04-19
BR112023021587A2 (pt) 2023-12-19
AR125379A1 (es) 2023-07-12
US20240199730A1 (en) 2024-06-20
CO2023015286A2 (es) 2024-02-05
CN117222665A (zh) 2023-12-12
SA523451188B1 (ar) 2025-06-22
WO2022223514A1 (en) 2022-10-27
AU2022263281A1 (en) 2023-11-09
TW202306982A (zh) 2023-02-16
PH12023552762A1 (en) 2024-04-15
CA3216894A1 (en) 2022-10-27
AU2022263281A9 (en) 2023-11-16
ECSP23086870A (es) 2023-12-29
JP2024516962A (ja) 2024-04-18

Similar Documents

Publication Publication Date Title
SA523451188B1 (ar) شظية ربط مولد الضد مضادة لـليمفوبويتين الغدة الصعترية ذو ثبات محسن
MX2025003310A (es) Integracion dirigida de acidos nucleicos
GB2569733A (en) RNA-guided nucleic acid modifying enzymes and methods of use thereof
GB2569734A (en) RNA-guided nucleic acid modifying enzymes and methods of use thereof
MY201637A (en) Natural killer cells and ilc3 cells and uses thereof
MX2022008508A (es) Enzimas y aplicaciones de las mismas.
PH12019502331A1 (en) Treatment of asthma with anti-tslp antibody
SA521422495B1 (ar) مستضدات البروستاتا المستحدثة واستخداماتها
MX2016001317A (es) Variantes de enzimas.
AR100606A1 (es) Variantes de lipasas y polinucleótidos que las codifican
MX2022010514A (es) Metodos de secuenciacion de biopolimeros.
EA202190736A1 (ru) Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью
MX2022000425A (es) Metodos y composiciones que comprenden un nivel reducido de proteinas de celulas hospedadoras.
WO2016168214A3 (en) Immunogenic fusion proteins for the treatment of cancer
MD20160014A2 (ro) Virus ARN oncolitic stabil genetic, metodă de producere şi de utilizare a acestuia
MY187334A (en) Xylanase
WO2015048523A3 (en) Mutant chondroitinase abc i compositions and methods of their use
MX2017014663A (es) Metodo para producir una proteina recombinante.
MX2018014229A (es) Metodo para la produccion de plantas haploides y haploides duplicadas posteriores.
MY178471A (en) Microorganisms for producing diamine and process for producing diamine using them
MY181148A (en) Microorganisms for producing diamine and process for producing diamine using them
WO2020185775A3 (en) Materials and methods for reducing nucleic acid degradation in bacteria
TW201613622A (en) Composition for skincare and pharmaceutical composition and preparation method thereof
AR104231A1 (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer